Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of Tirzepatide at Different Injection Sites
NCT04050670Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Sep 2019
- Primary completion
- Apr 2020
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of tirzepatide in type 2 diabetes mellitus (T2DM) and obesity (3 arms), sponsored by Eli Lilly and Company. Primary endpoints: Area Under the Concentration Versus Time Curve From Time Zero to Infinity at 480 hours and Maximum Concentration of Tirzepatide at 480 hours. Started Sep 2019; status: completed.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)obesity
Beyond the preview
Go deeper on NCT04050670.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04050670.